← Back to headlines
Cogent Biosciences Prepares for Bezuclastinib Launch Awaiting FDA Approval
Cogent Biosciences Inc. is gearing up for the launch of its drug Bezuclastinib, pending final approval from the FDA.
2 Mar, 07:57 — 2 Mar, 07:57
Sources
Showing 1 of 1 sources
